首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Graft Complexity-Related Outcomes of Fenestrated Endografting for Abdominal Aortic Aneurysms
【24h】

Graft Complexity-Related Outcomes of Fenestrated Endografting for Abdominal Aortic Aneurysms

机译:与腹主动脉瘤的腹腔内肠道生成的接枝复杂性相关结果

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To report the outcomes of fenestrated endovascular aneurysm repair (FEVAR) and compare early and midterm results in relation to stent-graft complexity. Methods: Between August 2006 and December 2014, 141 consecutive patients (mean age 72 +/- 7.6 years, range 50-89; 120 men) were treated electively with FEVAR for short-neck, juxtarenal, or suprarenal aortic aneurysms. Forty-five patients treated with stent-grafts featuring renal-only fenestrations were assigned to group A, while 96 patients receiving additional fenestrations for the superior mesenteric and/or celiac arteries were assigned to group B. Technical success, operative mortality and morbidity, target vessel patency, endoleak, reintervention, and survival were compared between the groups. Survival, target vessel stent patency, and reintervention during follow-up were estimated by Kaplan-Meier analysis; the estimates are presented with the 95% confidence interval (CI). Results: Technical success was achieved in 135 (95.7%) patients. Overall 30-day operative mortality was 3.5% (5/141). Perioperative complications occurred in 16 (12.1%) patients. Mean follow-up was 33 +/- 23 months. Overall estimated survival was 85.1% (95% CI 79.1% to 91.1%) at 1 year and 75.8% (95% CI 68.2% to 83.5%) at 3 years. Freedom from reintervention was 90.6% (95% CI 85.6% to 95.6%) at 1 year and 79.2% (95% CI 71% to 87.5%) at 3 years. There was no statistically significant difference between the groups in terms of perioperative mortality or morbidity, endoleak, survival, target vessel patency, or reintervention. Conclusion: The use of FEVAR for juxta-and suprarenal aneurysms is associated with low 30-day mortality/morbidity and high midterm efficacy. So far, perioperative and midterm results are not affected by the use of more complex fenestrated designs.
机译:目的:报告开窗血管内动脉瘤修复术(FEVAR)的结果,并比较与支架-移植物复杂性相关的早期和中期结果。方法:在2006年8月至2014年12月期间,141名连续患者(平均年龄72+/-7.6岁,范围50-89;120名男性)接受FEVAR治疗短颈动脉瘤、肾旁动脉瘤或肾上动脉瘤。45名采用仅肾脏开窗的支架移植物治疗的患者被分配到A组,96名接受肠系膜上动脉和/或腹腔动脉额外开窗的患者被分配到B组。比较两组之间的技术成功率、手术死亡率和发病率、靶血管通畅度、内漏、再干预和生存率。通过Kaplan-Meier分析评估随访期间的存活率、靶血管支架通畅率和再干预;估计值以95%置信区间(CI)表示。结果:135例(95.7%)患者获得技术成功。总的30天手术死亡率为3.5%(5/141)。围手术期并发症16例(12.1%)。平均随访33+/-23个月。总体估计生存率在1年时为85.1%(95%CI 79.1%至91.1%),在3年时为75.8%(95%CI 68.2%至83.5%)。1年时再干预的自由度为90.6%(95%可信区间85.6%至95.6%),3年时为79.2%(95%可信区间71%至87.5%)。在围手术期死亡率或发病率、内漏、存活率、靶血管通畅率或再干预方面,两组之间没有统计学显著差异。结论:FEVAR治疗肾旁动脉瘤和肾上腺动脉瘤具有较低的30天死亡率/发病率和较高的中期疗效。到目前为止,使用更复杂的开窗设计不会影响围手术期和中期结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号